We evaluated the expression of human glucocorticoid receptor beta (hGRP) in patients with severe autoimmune hepatitis (AIH). The subjects were 27 patients with AIH, including 6 with severe type (prothrombin time CPT] <40%) and 21 with non-severe type (PT::?:40%). Total RNA extracted from peripheral blood mononuclear cells (PBMCs) was reversed using reverse transcriptase. The resultant complementary DNA was amplified by reverse transcription polymerase chain reaction (RT -PCR) using specific primers for hGR a and p. The six patients with severe AIH were female; three presented fulminant hepatic failure with hepatic encephalopathy. In all patients with AIH, hGR a was detected. The incidence of hGR p expression in patients with non-severe type was 42.9% (9/21); it was 100% (6/6) in those with severe type. The positive ratio was significantly higher in severe-type patients. These results suggest that hGR p expression in PBMCs is a novel predictor of AIH severity.
INTRODUCTION
Glucocorticoids have been used often for management of patients with autoimmune hepatitis (AIH). However, some patients with AIH are refractory to glucocorticoids. Two highly homologous isoforms of glucocorticoid receptor (GR) exist in humans. Alternative splicing of human GR (hGR) pre-messenger RNA (mRNA) generates hGR a and hGR PI). The effects of glucocorticoids are 66 T. RAI et al. Recently, we reported that hGR /3 expression in the PBMCs of patients with AIR is closely associated with resistance to glucocorticoids. Furthermore, serum alanine aminotransferase (ALT) and total bilirubin (TB) levels were higher in hGR j3-positive patients with AIH than in hGR /3-negative 4 ). Therefore, we examined the expression of hGR j3 in patients with severe type of AIH in this study.
MATERIALS AND METHODS

Patients
This study was approved by the Ethics Committee of the Fukushima Medical University School of Medicine. Written informed consent was obtained from all subjects. The subjects were 27 patients with AIH, including 6 with severe-type (prothrombin time CPT] <40%, all women, aged 23-70 years) and 21 with nonsevere type (PT~40%) (3 men and 18 women, aged 28-77 years), as shown in Table 1 . These two groups were divided using PT according to the Japanese criteria 5 ) because it is possible for patients with severe type to progress to fulminant hepatitis. The diagnosis of AIH was based on criteria established by the International Autoimmune Hepatitis Group in 1999 6 ). Clinical characteristics of the six patients with severe type are shown in Table 2 . Resistance to glucocorticoids was defined as occurring when having recurrence by a steroid-loss process.
Preparation of PEMCs
Heparinized venous peripheral blood was obtained; the blood was diluted by addition of an equal volume of 0.9% NaCl. Blood samples were obtained at the recovery phase, less than 1 year after onset of AIH. The lone exception was Case 6, whose sample was obtained 1 month after liver transplantation. After careful layering over 3 ml of Lymphoprep (Amersham Pharmacia Biotech, Uppsala, Sweden), 6 ml of the diluted blood was centrifuged for 20 min at room temperature in a swing-out rotor. After centrifugation, the mononuclear cells formed a distinct band at the sample interface. The harvested fraction was diluted with buffered RPMI 1640 medium (Invitrogen Corp., Carlsbad, CA, USA) to reduce the solution density; the cells were pelletized by centrifugation for 10 min. Platelets were removed by layering the cells suspended in buffered RPMI 1640 medium and centrifugation for 15 min. The pellets were then used as mononuclear cells.
Isolation of Total RNA and Detection of hGR a and hGR /3 mRNA by PCR
Total RNA was extracted from PBMCs using ISOGEN-LS (Nippon Gene Co. Ltd., Toyama, Japan). Complementary DNA (cDNA) was synthesized using reverse transcriptase (SuperCript TMII; GIBCO Invitrogen Co., USA), 10 mM dNTP (GIBCO Invitrogen Co., USA) and random hexamer (GIBCO Invitrogen Co., USA). The cDNA was amplified in a polymerase chain reaction (PCR) using the following primer sets: 5' -CCT AAGGACGGTCTGAAGAGC-3' and 5' -CCACGT A TC-CTAAAAGGGCAC-3' for hGR a, 5'-TTTCTTATGGCATTTGCTCTGG -3' and 5'-CAACAATCTTGG CGCTCAAAA-3' for hGR /3, and 5'-TGAACCCCAAGGC-CAACCG C-3' and 5'-TTGTGCTGGGTGCCAGGGCA-3' for /3-actin, as described by Oakley et a[.7) . The PCR amplification was carried out with a reaction mixture comprising 0.4 JlI cDNA, 0.4 Jll primers (25 mmol/L), 1.6 JlI dNTP (2.5 mmol/L), 1' . RAJ et at. 
Statistical Analysis
Data va lues a re expressed as means±SD. Differences were compared using Fisher's exact probabili ty test and two-ta iled Welch's t-test; va lues of jJ < 0.05 were considered significa nt.
RESULTS
Representative results of RT-PCR products of hGR Q' and hGR (3 are shown in Fi g. 1. In all tested patient sa mp les, hGR Q' was detected; th e quantity of PCR products was equal , whereas hGR (3 was detected in some, but not in a ll , patient samples. In this stud y, the incidence of hGR (3 expression in patients with nonsevere type AIH was 42.9% (9/ 21) . However, that in patients with severe type was 100% (6/ 6) , as shown in Tab le 1. In hea lthy contro ls, we reported previously tha t the incidence of hGR (3 expression was 20% (2/ 10) 'I ) . The positive r atio was significa ntly high (jJ < 0.05) in patients with severe type. These patients were a ll fe ma le; three of them (cases 3, 5, a nd 6) presented fu lmin ant hepa ti c fa il ure with hepatic encepha lopathy, as shown in Table 2 . All patients with severe type were trea ted initi ally using steroid pulse therapy with or with out pl asma exchange. They were subsequentl y given predn iso lone plus azathi oprine. Fi ve of them improved ; one did not respond and under went li ver transplantation. DISCUSSION This is the first report describing hGR 13 expression in patients with severe-type AIH. It remains unknown why hGR 13 is highly expressed in PBMes from patients with severe type. Previously, we showed that hGR 13 expression in the PBMes of patients with AIH was closely associated with resistance to glucocorticoids, and that serum ALT and TB levels were significantly higher in hGR f3-positive patients'). In this study, no significant difference was found in AL T levels between severe AIH and non-severe AIH, although a significant difference was found in incidence of hGR 13 expression between both groups. That lack of difference pertains because AL T does not show different severity from PT. The expression of hGR 13 was reported to increase in response to several inflammatory cytokines, such as tumor necrosis factor-a and interleukin-pl. The high levels of these inflammatory cytokines in the sera of patients with severe type of AIH might contribute to expression of hGR 13.
Hassain et al. report that high circulating levels of various cytokines, including ILl and TNF-a, are found in patients with AIH and seem to correlate with disease activity9). In addition, some reports of interaction exist between hGR and steroid However, these factors might not affect expression of hGR 13 because our blood samples were obtained at the recovery phase less than I year after onset of AIH.
In this study, no significant differences were found in hGR f3-positive severe AIH and non-severe AIH. In addition to hGR 13 expression, many other factors are involved in glucocorticoid resistance. A polymorphism in the hGR gene in exon 913, in an "ATTTA" motif, was associated significantly with rheumatoid arthritisI2). Also, GR participates in signal transduction pathways such as the activation protein-I (AP-I) pathway and the nuclear factor-kappaB (NF-xB) pathway. Levels and functional states of such GR-interacting proteins might have important effects on glucocorticoid resistance I3 ). In addition, it is reported that mutation of hGR a causes glucocorticoid resistance by affecting multiple steps in the cascade of the GR signaling pathway14). The roles of these factors in AIH must be studied in the future.
In most Japanese patients with severe AIH, encephalopathy develops on or subsequent to day 11 after the onset. The presence of fulminant hepatic failure because of AIH indicates a poor prognosis. Because hGR 13 expression was observed in all patients with severe AIH in this study, hGR 13 expression in PBMes is likely to serve as a novel predictor of AIH severity. In patients with acute onset type of AIH, hGR 13 expression should be examined in the early stages. If it is present, additional therapy, such as steroid pulse therapy or azathioprine therapy,
